Edgen Stock·Sep 26 2025, 15:52戻る
戻る
Factor Bioscience Initiates Patent Infringement Lawsuit Against Cellectis and AstraZeneca
Edgen Stock·Sep 26 2025, 15:52
[1] Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents[2] AstraZeneca, Cellectis Sued Over $2.2 Billion Cancer-Drug Deal - Bloomberg Law News[3] Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents - PR Newswire